Skip to main content

Table 1 Summary of completed phase IIb / III HIV-1 vaccine trials

From: Development of prophylactic vaccines against HIV-1

Vaccine trial Candidate vaccine(s) Phase N volunteers Intended immune response Result
VAX 003 Protein: rgp120 III 2500 Antibodies, CD4+ T cells No efficacy
VAX 004 Protein: rgp120 III 5400 Antibodies, CD4+ T cells No efficacy
RV144 Pox/protein: ALVAC/rgp120 III 16,403 Antibodies, CD4+ & CD8+ T cells 31% efficacy
HVTN 502/ Merck 023 Adenovirus type 5 (Ad5) gag/pol/nef IIb 3000 CD8+ & CD4+ T cells No efficacy
HVTN 503 Ad5 gag/pol/nef IIb 3000 CD8+ & CD4+ T cells No efficacy
HVTN 505 DNA-Ad5 gag/pol/nef/env IIb 2504 Antibodies, CD4+ & CD8+ T cells No efficacy